Annovis doubles as lead drug improves Parkinson's [Seeking Alpha]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Seeking Alpha
and effective in improving the physical and cognitive functions of patients with early Parkinson's disease. Updating data from its Phase 3 PD trial, Annovis ( ANVS ) said buntanetap, designed to target neurotoxic proteins, maintained cognition in the entire patient population at 10 and 20 mg doses, while those on placebo deteriorated throughout the study. At 20 mg, the study drug “showed significant improvement in cognition compared to placebo,” the company added. With a consistent tolerability profile across early and advanced PD patients, buntanetap led to statistically significant improvements in all primary and secondary endpoints in specific subgroups, according to Annovis Bio ( ANVS The company has scheduled a webcast at 4:30 PM ET on July 2 to discuss additional results. Recommended For You Recommended For You More Trending News About ANVS Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and MorePR Newswire
- Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative DiseasesGlobeNewswire
- Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative CombinationsGlobeNewswire
ANVS
Earnings
- 5/10/24 - Beat
ANVS
Sec Filings
- 9/30/24 - Form 8-K
- 8/15/24 - Form 8-K
- 8/14/24 - Form 10-Q
- ANVS's page on the SEC website